
The U.S. Food and Drug Administration approved Infilbray (venglustat) tablets on 18 November 2026 as the first treatment for the neurological symptoms of Type 3 Gaucher disease, in adults and children weighing at least 15 kg. The approval, granted to Sanofi’s Genzyme Corporation seven days before the agency’s 25 November target date, rests on a 43-patient randomized trial and gives rare-disease investigators a fresh regulatory precedent.
What happened
In a news release dated 18 November 2026, the FDA announced that it had approved Infilbray, an oral glucosylceramide synthase inhibitor that crosses the blood-brain barrier, for the neurological symptoms of Type 3 Gaucher disease (GD3). The agency said the approval was granted to Genzyme Corporation, a Sanofi company, and that the product holds Orphan Drug designation and was reviewed under Priority Review.
Acting FDA Commissioner Kyle Diamantas said in the release: “For patients with Type 3 Gaucher disease, harmful substances build up in the brain without a way to stop them, but this drug’s ability to cross the blood-brain barrier means it can get to the source of the buildup driving the neurological symptoms.” He added that the approval “reflects the FDA’s commitment to advancing therapeutic options for patients with rare diseases.”
The timing is notable. When the FDA accepted the application for priority review, Sanofi’s 28 May 2026 announcement gave a target action date of 25 November 2026, so the decision arrived a week early.
Key details of the evidence
The FDA says the approval is supported by a randomized, double-blind, multicenter clinical study of 43 patients aged 12 years and older with GD3 who had previously been treated with enzyme replacement therapy (ERT) and had reached systemic disease stabilization. Participants received either oral Infilbray or intravenous ERT for 52 weeks. Effectiveness was judged with two assessments that capture the neurological symptoms central to GD3, one covering ataxia (loss of muscle control and coordination) and one covering cognitive function. At Week 52, patients treated with Infilbray showed improvement on a measure combining both assessments, compared with patients taking ERT.
The study is the LEAP2MONO trial, registered on ClinicalTrials.gov as NCT05222906, where it is described as a phase 3, multicenter, multinational, randomized, double-blind, double-dummy, active-comparator study in patients who had reached therapeutic goals with ERT. The registry lists 43 enrolled participants and a status of active, not recruiting.
Sanofi’s earlier announcement names the primary endpoints as the change from baseline to week 52 in the modified total score on the Scale for the Assessment and Rating of Ataxia (SARA) and in the total scale index score of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). It reported that patients must have received ERT for at least three years and met therapeutic goals for systemic disease, and that venglustat met both primary endpoints and three of four key secondary endpoints. Those secondary measures covered spleen volume, liver volume, platelet count, hemoglobin and, as biomarkers, cerebrospinal fluid and plasma levels of GL1 and lyso-GL1.
| Item | What the sources report |
|---|---|
| Product and sponsor | Infilbray (venglustat) tablets; Genzyme Corporation, a Sanofi company (FDA) |
| Approved population | Adults and pediatric patients weighing at least 15 kg with neurological symptoms of Type 3 Gaucher disease (FDA) |
| Pivotal study | 43 patients aged 12 and older, randomized, double-blind, 52 weeks, compared with ERT (FDA; ClinicalTrials.gov NCT05222906) |
| Review designations | Orphan Drug and Priority Review (FDA); Breakthrough Therapy and Fast Track granted earlier (Sanofi, Global Genes) |
| Target action date | 25 November 2026, per Sanofi’s 28 May 2026 announcement |
Safety information in the FDA release
The FDA lists gastrointestinal symptoms and adverse effects on mood as the most frequently reported side effects, and says serious psychiatric risks, including suicidal ideation and behavior, have been reported. It adds that animal studies identified potential clouding of vision in younger patients and adverse effects on fetal development when the drug is taken during pregnancy, and points readers to the drug labeling for more detail. In the trial, Sanofi reported headache in 14.3% of the venglustat arm and 18.2% of the ERT arm, nausea in 14.3% versus 4.5%, and splenomegaly and diarrhea in 14.3% versus none.
Background and context
Gaucher disease is a rare lysosomal storage disorder in which fatty substances called glycosphingolipids accumulate in organs including the spleen, liver, bone marrow and lungs. Global Genes’ RARE Daily reported on 20 March 2026 that Type 3 is the chronic neuronopathic form, combining those systemic problems with progressive neurological symptoms, and that enzyme replacement therapies do not effectively reach the brain, leaving neurological symptoms largely untreated. That report covered the FDA’s Breakthrough Therapy designation for venglustat in GD3, which followed Fast Track and Orphan Drug designations.
Trade outlet pharmaphorum, writing on 28 May 2026, described venglustat as having a checkered research history, with failed trials in autosomal dominant polycystic kidney disease, GM2 gangliosidosis, Parkinson’s disease and Fabry disease, and said those setbacks had undermined Sanofi’s earlier view of the molecule as a “pipeline-in-a-pill”. It noted that Sanofi Genzyme already sells the enzyme replacement therapy Cerezyme (imiglucerase) and the oral therapy Cerdelga (eliglustat) for Gaucher disease, and that sales expectations for GD3 alone are relatively modest.
Reaction
Beyond the FDA’s statement, the clearest public position from the sponsor predates the approval. Karin Knobe, Sanofi’s global head of clinical development for rare diseases, said when the Breakthrough Therapy designation was announced that it “recognizes the significant unmet medical need for people living with type 3 Gaucher disease, particularly those experiencing progressive neurological deterioration,” as quoted by Global Genes. Sanofi’s May announcement said that, if approved, venglustat would become the first treatment available in the US to address the progressive neurological manifestations of GD3.
What it means for researchers, universities and research offices
Trial design precedent. The approval rests on an active-comparator, double-dummy design in a small population that was already stabilized on ERT, with paired neurological endpoints for motor and cognitive function measured over 52 weeks. Investigators and academic medical centers planning studies in neuronopathic lysosomal storage disorders now have a concrete example of the evidence package that supported an FDA approval. Teams drafting protocols can compare it with the guidance in the CASRAI explainers on designing a clinical trial and rare disease research.
Expedited pathways. The product combined Orphan Drug designation, Breakthrough Therapy, Fast Track and Priority Review. Regulatory-affairs and sponsored-programs staff supporting rare-disease investigators can use this case alongside the CASRAI guides to FDA expedited programs and orphan drug designation, and the definition of FDA priority review.
Safety language and consent. The FDA’s emphasis on psychiatric risks, including suicidal ideation and behavior, and on vision and fetal-development findings from animal studies is relevant to research offices and ethics committees that review studies of related compounds. They will want to compare current protocol risk language and monitoring plans with the approved labeling once it is reviewed.
Registry records. The LEAP2MONO registration remains active, not recruiting, and Sanofi has said open-label results will be presented when available. Sites and sponsors keeping registry entries current can refer to the CASRAI note on ClinicalTrials.gov.
What happens next
Sanofi’s May announcement said venglustat was under regulatory review for GD3 in the European Union, and that the company would pursue additional global filings in 2026. It also said results from the LEAP2MONO open-label phase would be presented in the future. The FDA directs prescribers and patients to the approved drug labeling for the full side-effect information.
Sources
- U.S. Food and Drug Administration, “FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease”, 18 November 2026
- Sanofi, “Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease”, 28 May 2026
- pharmaphorum, “November date set for FDA decision on Sanofi’s Gaucher drug”, 28 May 2026
- Global Genes RARE Daily, “FDA Grants Breakthrough Therapy for Sanofi’s Type 3 Gaucher Disease Drug”, 20 March 2026
- ClinicalTrials.gov, study record NCT05222906 (LEAP2MONO)







